Paxman Q2 - Nothing spectacular, but in the right direction

Redeye provides an update following Paxman’s Q2 2025 report. We argue the report is decent, and the company’s solid long-term outlook remains intact. While the figures came in somewhat below our estimates, the overall direction of the business is unchanged. Based on the report, we have made some downward adjustments to our sales estimates, rendering slight changes to our fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/